| Insiders | Shares | % | Avg Price | Total $ | |
|---|---|---|---|---|---|
| Buys | 0 | ||||
| Sells | 1 | -7.52K | 100% | $6.94 | -$52.2K |
| Net | -1 | -7.52K | -100% | -$52.2K |
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Report Date |
|---|---|---|---|---|---|
| Longitude Capital Partners III, LLC | 10%+ Owner | $14.9M | Apr 19, 2022 | ||
| Pivotal bioVenture Partners Fund I, L.P. | Director | $5.61M | Aug 1, 2023 | ||
| Robert Hopfner | Director | $5.61M | Jun 18, 2024 | ||
| Henric Bjarke | Svp, Coo | $376K | Dec 15, 2022 | ||
| Douglas A. Treco | CEO, Director | $349K | -$52.2K | -13% | Sep 30, 2024 |
| Sanjay Subramanian | Svp, Cfo | $109K | Mar 13, 2024 | ||
| Matthew Winton | Coo | $21.8K | Sep 30, 2024 | ||
| Sarah Bhagat | Director | Jun 18, 2024 | |||
| Stephen J. DiPalma | Interim CFO | May 17, 2021 | |||
| Lynne Sullivan | Director | Jun 18, 2024 | |||
| Inozyme Pharma, Inc. | Director | Jun 23, 2021 | |||
| Edward T. Mathers | Director | Jun 18, 2024 | |||
| Reinaldo M. Diaz | Director | Jun 18, 2024 | |||
| Martin Edwards | Director | Jun 18, 2024 | |||
| Axel Bolte | Director | Jun 18, 2024 | |||
| Erik Harris | Director | Oct 3, 2024 |
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|